IndraLab
Statements
4
|
14
4
reach
"As for drug sensitivity analysis, SFXN4 was predicted to be responsive to Vorinostat (an inhibitor targeting HDAC 1, HDAC2, HDAC3, HDAC6, HDAC7, and HDAC11), Methotrexate (adihydrofolate reductase inhibitor), 5-Fluorouracil (athymidylate synthase inhibitor) and TPCA-1 (an inhibitor for IKK2), while resistant to TGX221 (a Keap1-Nrf2 inhibitor) and Dasatinib (a dual inhibitor for Src/Bcr-Abl), suggesting that SFXN4 might be a biomarker for drug screening (Figure 7B)."
reach
"However, StA-IFN-1 and -4 (XREF_FIG, XREF_FIG) behaved as expected and were further examined by comparing their activity to the inhibitors TPCA-1, which inhibits the IFN induction pathway component IKKbeta, 15 and ruxolitinib, which inhibits IFN signaling pathway component Jak1 16 (XREF_FIG, XREF_FIG)."
reach
"To determine if the rapid induction of apoptosis in macrophages and DC was NF-kappaB and IKK inhibition dependent and not an off-target effect of TAT-NBD, five additional NF-kappaB inhibitory compounds were tested : Compound A (CmpA) and TPCA-1, both of which inhibit IKKbeta; MG-132, which inhibits IkappaBalpha proteosomal degradation; and IKKiVII and Wedelolactone, which inhibit both IKKalpha and IKKbeta (see XREF_SUPPLEMENTARY)."